focus -WSS

focus

author：comprehensive 2025-10-03 01:03:51 - browse：7

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

focus

explore

WSS

CommonSpirit Health keeps growing, even as it loses money

Beware reading your test results before your doctor does

A letter from the executive editor: The 2023 STATUS List

Drug for rare kidney disease narrowly misses mark in clinical trial

What affirmative action's end means to a medical student

Experts study whether long Covid risk adds up with each reinfection

focus

focus

Wikipedia

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UpToDate has a racism problem: Dr. Stanley Goldfarb

Medical records are filled with copy

Hearing on Medicare drug price negotiation gets unusually heated

Psychedelics group wrestles with new pharma identity

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why are Kaiser Permanente staff considering a strike?

As demand for Covid shots wanes, Moderna seeks its next success

Drug cartel violence flares in western Mexico after vigilante leader's killing

hotspot

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

AstraZeneca lung cancer study comes in below expectations

Changes to biosimilar regulatory framework must prioritize patients

Drug cartel violence flares in western Mexico after vigilante leader's killing

Drug cartel violence flares in western Mexico after vigilante leader's killing

The biotech scorecard for Q3: 15 stock

focus

explore

explore

focus